BACKGROUND: We previously demonstrated that Cervarix(®) elicits antibody responses against vaccine-related types for which clinical efficacy was demonstrated (HPV-31 and -45). Here, we evaluated the kinetics of neutralization titers and avidity of Cervarix(®)-induced antibodies up to 36 months of follow-up in unexposed and HPV infected women. METHODS: A subset of women who participated in the Cost Rica HPV-16/18 Vaccine Trial had pre- and post-vaccination sera tested for antibody responses to HPV-16, -18, -31, -45, and -58 using a pseudovirion-based neutralization assay, and HPV-16 antibody avidity using an HPV-16 L1 VLP (virus-like particle)-based ELISA developed in our laboratory. RESULTS: In uninfected women, neutralizing antibody titers did not reach significance until after the 3rd dose for HPV-31 (month 12, p=0.009) and HPV-45 (month 12, p=0.003), but then persisted up to month 36 (HPV-31, p=0.01; HPV-45, p=0.002). Individuals infected with HPV-16 or HPV-31 at enrollment developed a significantly higher median antibody response to the corresponding HPV type after one dose, but there was not a difference between median titers after three doses compared to the HPV negative group. Median HPV-16 antibody avidity and titer increased over time up to month 12; however, the HPV-16 avidity did not correlate well with HPV-16 neutralizing antibody titers at each time point examined, except for month 6. The median avidity levels were higher in HPV-16 infected women at month 1 (p=0.04) and lower in HPV-16 infected women at month 12 (p=0.006) compared to the HPV negative women. CONCLUSIONS: The persistence of cross-neutralization titers at month 36 suggests cross-reactive antibody responses are likely to persist long-term and are not influenced by infection status at enrollment. However, the weak correlation between avidity and neutralization titers emphasizes the need for examining avidity in efficacy studies to determine if high avidity antibodies play a critical role in protection against infection.
BACKGROUND: We previously demonstrated that Cervarix(®) elicits antibody responses against vaccine-related types for which clinical efficacy was demonstrated (HPV-31 and -45). Here, we evaluated the kinetics of neutralization titers and avidity of Cervarix(®)-induced antibodies up to 36 months of follow-up in unexposed and HPV infectedwomen. METHODS: A subset of women who participated in the Cost Rica HPV-16/18 Vaccine Trial had pre- and post-vaccination sera tested for antibody responses to HPV-16, -18, -31, -45, and -58 using a pseudovirion-based neutralization assay, and HPV-16 antibody avidity using an HPV-16 L1 VLP (virus-like particle)-based ELISA developed in our laboratory. RESULTS: In uninfected women, neutralizing antibody titers did not reach significance until after the 3rd dose for HPV-31 (month 12, p=0.009) and HPV-45 (month 12, p=0.003), but then persisted up to month 36 (HPV-31, p=0.01; HPV-45, p=0.002). Individuals infected with HPV-16 or HPV-31 at enrollment developed a significantly higher median antibody response to the corresponding HPV type after one dose, but there was not a difference between median titers after three doses compared to the HPV negative group. Median HPV-16 antibody avidity and titer increased over time up to month 12; however, the HPV-16 avidity did not correlate well with HPV-16 neutralizing antibody titers at each time point examined, except for month 6. The median avidity levels were higher in HPV-16 infected women at month 1 (p=0.04) and lower in HPV-16 infected women at month 12 (p=0.006) compared to the HPV negative women. CONCLUSIONS: The persistence of cross-neutralization titers at month 36 suggests cross-reactive antibody responses are likely to persist long-term and are not influenced by infection status at enrollment. However, the weak correlation between avidity and neutralization titers emphasizes the need for examining avidity in efficacy studies to determine if high avidity antibodies play a critical role in protection against infection.
Authors: Claire-Anne Siegrist; Maria Pihlgren; Chantal Tougne; Sue M Efler; Mary Lou Morris; Mohammed J AlAdhami; D William Cameron; Curtis L Cooper; Jenny Heathcote; Heather L Davis; Paul-Henri Lambert Journal: Vaccine Date: 2004-12-16 Impact factor: 3.641
Authors: Ligia A Pinto; Raphael Viscidi; Clayton D Harro; Troy J Kemp; Alfonso J García-Piñeres; Matthew Trivett; Franklin Demuth; Douglas R Lowy; John T Schiller; Jay A Berzofsky; Allan Hildesheim Journal: Virology Date: 2006-07-24 Impact factor: 3.616
Authors: Troy J Kemp; Alfonso García-Piñeres; Roni T Falk; Sylviane Poncelet; Francis Dessy; Sandra L Giannini; Ana Cecilia Rodriguez; Carolina Porras; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Vaccine Date: 2008-05-19 Impact factor: 3.641
Authors: H P Roost; M F Bachmann; A Haag; U Kalinke; V Pliska; H Hengartner; R M Zinkernagel Journal: Proc Natl Acad Sci U S A Date: 1995-02-28 Impact factor: 11.205
Authors: Nubia Muñoz; Ricardo Manalastas; Punee Pitisuttithum; Damrong Tresukosol; Joseph Monsonego; Kevin Ault; Christine Clavel; Joaquin Luna; Evan Myers; Sara Hood; Oliver Bautista; Janine Bryan; Frank J Taddeo; Mark T Esser; Scott Vuocolo; Richard M Haupt; Eliav Barr; Alfred Saah Journal: Lancet Date: 2009-06-01 Impact factor: 79.321
Authors: Judith F Smith; Michelle Brownlow; Martha Brown; Rose Kowalski; Mark T Esser; Wanda Ruiz; Eliav Barr; Darron R Brown; Janine T Bryan Journal: Hum Vaccin Date: 2007-02-24
Authors: Rolando Herrero; Allan Hildesheim; Ana C Rodríguez; Sholom Wacholder; Concepción Bratti; Diane Solomon; Paula González; Carolina Porras; Silvia Jiménez; Diego Guillen; Jorge Morales; Mario Alfaro; Jean Cyr; Kerrygrace Morrisey; Yenory Estrada; Bernal Cortés; Lidia Ana Morera; Enrique Freer; John Schussler; John Schiller; Douglas Lowy; Mark Schiffman Journal: Vaccine Date: 2008-07-18 Impact factor: 3.641
Authors: Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin Journal: Lancet Date: 2007-06-30 Impact factor: 79.321
Authors: L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr Journal: Br J Cancer Date: 2006-11-21 Impact factor: 7.640
Authors: Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Upasana Ray; Paola Cinque; Simonetta Gerevini; Valeria Longo; Adriano Lazzarin; Sven Schippling; Roland Martin; Christopher B Buck; Diana V Pastrana Journal: Sci Transl Med Date: 2015-09-23 Impact factor: 17.956
Authors: Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto Journal: Cancer Prev Res (Phila) Date: 2013-11